WellPoint's Comparative Effectiveness Research Guidelines Describe How It Will Determine Usefulness Of Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
The largest provider of health benefits in the U.S. will use the CER guidelines when evaluating drugs for its formulary.
You may also be interested in...
Venture Capitalists Have A Growing Interest In Comparative Effectiveness
Venture capitalists are taking a growing interest in the impact of comparative effectiveness research on future drug products and how results might affect products' ability to gain coverage by third-party payers
Venture Capitalists Have A Growing Interest In Comparative Effectiveness
Venture capitalists are taking a growing interest in the impact of comparative effectiveness research on future drug products and how results might affect products' ability to gain coverage by third-party payers
WellPoint Will Put Comparative Effectiveness Guidance In Updated Drug Assessment Criteria
The health insurer's next iteration of its technology assessment criteria, used for evaluating drugs for formulary inclusion, will likely be published by the end of the year.